Infertility Clinical Trials

Find Infertility Clinical Trials Near You

Growth Hormone and Dehydroepiandrosterone Effect on Poor Ovarian Reserve Patients During in Vitro Fertilization

Status: Recruiting
Location: See location...
Intervention Type: Drug, Dietary supplement
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 35
Healthy Volunteers: f
View:

⁃ At least two of the following three criteria had to be present after maximal stimulation:

• Advanced maternal age (\>40 years) or any other risk factor for Poor Ovarian Response (POR).

• ≤3 oocytes with a conventional stimulation protocol).

• An abnormal ovarian reserve test \[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml\].

Locations
Other Locations
Egypt
Beni-Suef University Hospital
RECRUITING
Banī Suwayf
Time Frame
Start Date: 2025-10-10
Estimated Completion Date: 2026-11-12
Participants
Target number of participants: 165
Treatments
Experimental: Somatropin group
Somatropin (4IU for 1 month) 1 S.C injection every 3 days for at least 1 month plus, folic acid 400mcg/day
Experimental: dehydroepiandrosterone
dehydroepiandrosterone 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
Active_comparator: Standard care
Patients will receive standard care will receive folic acid 400 mcg per day
Related Therapeutic Areas
Sponsors
Leads: Beni-Suef University

This content was sourced from clinicaltrials.gov